

### Melanoma and mycosis fungoides AJCC staging

By Parin Pearl Rimtepathip, MD, and Janna Mieko Vassantachart, MD

#### American Joint Committee on Cancer (AJCC) 8th Ed. - Melanoma Staging

Clinical staging			
<b>Stage 0</b>	Tis	N0	M0
<b>Stage 1A</b>	T1a	N0	M0
<b>1B</b>	T1b, T2a	-	-
<b>Stage 2A</b>	T2b, T3a	N0	M0
<b>2B</b>	T3b, T4a	-	-
<b>2C</b>	T4b	-	-
<b>Stage 3</b>	Any T	≥ N1	M0
<b>Stage 4</b>	Any T	Any N	M1

Pathologic staging (only differs for stage 3)			
<b>3A</b>	T1a/b, T2a	N1a, N2a	M0
<b>3B</b>	T0, T1a/b, T2a	N1b/c	-
	T1a/b, T2a	N2b	-
	T2b, T3a	N1a-c, N2a/b	-
<b>3C</b>	T0	N2b/c, N3b/c	-
	T1a/b, T2a/b, T3a	N2c, N3a-c	-
	T3b, T4a	Any N	-
	T4b	N1a-c, N2a-c	-
<b>3D</b>	T4b	N3a-c	-

Definitions		
Primary Tumor (T)	Thickness (mm)	Ulceration
<b>TX</b>	Primary tumor cannot be assessed	
<b>T0</b>	No evidence of primary tumor	
<b>Tis</b>	Melanoma in situ	
<b>T1</b>	≤1.0	a: Breslow < 0.8 mm w/o ulceration b: Breslow 0.8-1.0 mm w/o ulceration or ≤1.0 mm w/ ulceration
<b>T2</b>	1.1-2.0	a: w/o ulceration
<b>T3</b>	2.1-4.0	b: w/ ulceration
<b>T4</b>	>4.0	
Regional Lymph Nodes (N)	Number of regional nodes	Microsatellite instability (MSI)* status, clinically detectable
<b>NX</b>	Nodes cannot be assessed	
<b>N0</b>	No regional metastases detected	
<b>N1</b>	0-1 node	a: no MSI, clinically occult b: no MSI, clinically detected c: MSI present, 0 nodes
<b>N2</b>	2-3 nodes	a: no MSI, clinically occult b: no MSI, clinically detected c: MSI present, detectable or occult
<b>N3</b>	>3 nodes	a: no MSI, all occult b: no MSI, ≥ 1 detected or matted c: MSI present, detectable or occult
Distant Metastasis (M)	Site of metastases	Serum LDH
<b>M0</b>	No distant metastases detected	
<b>M1a-d</b>	(a) Skin/subcutaneous/distant node, (b) lung, (c) other visceral sites, (d) brain	Not assessed
<b>M1a-d (0)</b>		Normal
<b>M1a-d (1)</b>		Elevated

\*MSI refers to any satellite, locally recurrent, or in transit lesions.

#### Quick tips for melanoma staging:

- 8<sup>th</sup> Ed omits mitosis status and T1a is <0.8 mm rather than ≤1.0mm
- Clinical and pathologic staging (TNM) is the same except for stage 3
- Nodal involvement → at least stage 3
- Distant metastases → stage 4



**Parin Pearl Rimtepathip, MD**, is a PGY-2 dermatology resident at Loma Linda University.



**Janna Mieko Vassantachart, MD**, is a PGY-2 dermatology resident at Loma Linda University.

## Melanoma and mycosis fungoides AJCC staging (cont.)

By Parin Pearl Rimtepathip, MD, and Janna Mieko Vassantachart, MD

### Mycosis fungoides staging

Staging Classification			
<b>Stage 1A</b>	T1	N0	M0
<b>1B</b>	T2	N0	M0
<b>Stage 2A</b>	T1-2	N1	M0
<b>2B</b>	T3	N0-1	M0
<b>Stage 3A</b>	T4	N0	M0
<b>3B</b>	T4	N1	M0
<b>Stage 4A</b>	T1-4	N0-3	M0
<b>4B</b>	T1-4	N0-3	M1

Definitions	
<b>Skin Tumor (T)</b>	
T1	Limited patch/plaque (involving <10% of total skin surface)
T2	Generalized patch/plaque (involving >10% of total skin surface)
T3	Tumor(s)
T4	Erythroderma (>90% BSA)
<b>Regional lymph node (N)</b>	
N0	No enlarged lymph nodes
N1	Enlarged lymph nodes, histologically uninvolved
N2	Enlarged lymph nodes, histologically involved (nodal architecture unaffected)
N3	Enlarged lymph nodes, histologically involved (nodal architecture effaced)
<b>Visceral involvement (M)</b>	
M0	No visceral involvement
M1	Visceral involvement
<b>Blood (B)*</b>	
B0	No circulating atypical (Sezary) cells or <5% of lymphocytes
B1	Low blood tumor burden (>5% of lymphocytes are Sezary cells, but not B2)
B2	High blood tumor burden (1000/mL Sezary cells and positive clone)

\* Is not part of stage classification for AJCC (useful in ACS and EORTC)

#### Quick tips for MF staging:

- Nodal involvement → at least stage IIA
- Cutaneous tumors → at least stage IIB
- Erythroderma → at least stage IIIA
- Visceral involvement → stage IVB

#### References:

Amin, Mahul, et al. *AJCC Cancer Staging Manual, 8th Ed.* Springer International Publishing, 2017.